Has Laura Thomas received payments from drug or device companies?

Yes. Drug and device makers reported $3,481 in general payments to Laura Thomas across 102 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Laura Thomas did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Laura Thomas come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Laura Thomas

Neurology with Special Qualifications in Child Neurology · Chattanooga, TNNPI 1184010456

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,791 of the $3,481 with a category attached, or 80.2%. 25 manufacturers reported payments, led by Livanova USA, Inc. at 28.8% of the total. Reporting peaked in 2022 at $1,696 and has fallen 90.5% since, to $161 in 2025.

$3,481in general payments, 2019–2025

Across 102 payments — averaging $34.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Livanova USA, Inc.$1K
UCB, Inc.$958
Jazz Pharmaceuticals Inc.$236
Neurelis, Inc.$206
Eisai Inc.$139
Abbott$135
plus $806 from 19 others

What the payments were for

Travel & lodging$69120%
Food & beverage$2,79180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Livanova USA, Inc.	3	$1,002
UCB, Inc.	33	$958
Jazz Pharmaceuticals Inc.	11	$236
Neurelis, Inc.	8	$206
Eisai Inc.	7	$139
Abbott	2	$135
Sumitomo Pharma America, Inc.	8	$114
AbbVie	4	$90
Zogenix Inc.	1	$84
Supernus Pharmaceuticals, Inc.	4	$53
Catalyst Pharmaceuticals, Inc.	2	$53
Sarepta Therapeutics, Inc.	2	$52
Mannkind Corporation	2	$46
Immedica Pharma US, Inc.	1	$45
Biogen	2	$43
Sunovion Pharmaceuticals Inc.	3	$33
Upsher-smith Laboratories LLC	1	$28
Novartis Gene Therapies, Inc. (fka Avexis, Inc.)	1	$24
Biohaven Pharmaceutical Holding Company Ltd.	1	$24
Greenwich Biosciences, Inc.	1	$23
Neurocrine Biosciences, Inc.	1	$22
SK Life Science, Inc.	1	$21
Amneal Pharmaceuticals LLC	1	$18
Medtronic	1	$18
Novartis	1	$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

VNS Therapy$1,002
CARDIOMEMS$126

How this compares

$3,481 in reported general payments places this provider in the 65th percentile of 47 neurology with special qualifications in child neurology providers in Tennessee.

See all neurology with special qualifications in child neurology providers in Tennessee →

Other neurology with special qualifications in child neurology in Chattanooga

Thomas IrelandChattanooga$120K
Day BreenChattanooga$8K
Lewis MillerChattanooga$8K
Jesus Pina GarzaNashville$1.4M
James WhelessMemphis$1.2M
Richard FinkelMemphis$353K
Jeffrey NeulNashville$127K
James FryNashville$80K
Willie AndersonJohnson City$26K
William BurnetteNashville$23K

See the full list for Tennessee →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →